(19) World Intellectual Property Organization International Bureau





(43) International Publication Date 2 August 2001 (02.08.2001)

PCT

(10) International Publication Number WO 01/54472 A3

(51)	International Pat C07H 21/02	ent Classification ⁷ : C120	Q 1/68,	60/226,681 60/227,182	22 August 2000 (22.08.2000) 22 August 2000 (22.08.2000)	US US
	CO/11 21/02			60/227,009	23 August 2000 (23.08.2000)	US
(21)	International App	olication Number: PCT/US0	1/01307	60/228,924	30 August 2000 (30.08.2000)	US
(21)	International App	nication Number. 1017030.	1/01507	60/229,343	1 September 2000 (01.09.2000)	US
		D : 17.1 2001 (17.0	1 2001)	60/229,344	1 September 2000 (01.09.2000)	US
(22)	International Fili	ng Date: 17 January 2001 (17.0	11.2001)	60/229,287	1 September 2000 (01.09.2000)	US
				60/229,345	1 September 2000 (01.09.2000)	US
(25)	Filing Language:		English	60/229,513	5 September 2000 (05.09.2000)	US
				60/229,519	5 September 2000 (05.09.2000)	US
(26)	Publication Lang	uage:	English	60/230,438	6 September 2000 (06.09.2000)	US
, ,	_	_		60/230,437	6 September 2000 (06.09.2000)	US
(30)	Priority Data:			60/231,413	8 September 2000 (08.09.2000)	US
(00)	60/179,065	31 January 2000 (31.01.2000)) US	60/232,080	8 September 2000 (08.09.2000)	US
	60/180,628	4 February 2000 (04.02.2000	·	60/232,080	8 September 2000 (08.09.2000)	US
	60/184,664	24 February 2000 (24.02.2000		60/231,242	8 September 2000 (08.09.2000)	US
	60/186,350	2 March 2000 (02.03.2000		60/231,244	8 September 2000 (08.09.2000)	US
	60/189,874	16 March 2000 (16.03.2000		*	8 September 2000 (08.09.2000)	US
	60/190,076	17 March 2000 (17.03.2000		60/231,414	8 September 2000 (08.09.2000)	US
	60/198,123	18 April 2000 (18.04.2000		60/231,243	12 September 2000 (12.09.2000)	US
=	60/205,515	19 May 2000 (19.05.2000		60/231,968	12 September 2000 (12.09.2000) 14 September 2000 (14.09.2000)	US
	60/209,467	7 June 2000 (07.06.2000		60/232,400	-	US
	60/214,886	28 June 2000 (28.06.2000		60/232,397	14 September 2000 (14.09.2000)	US
	60/215,135	30 June 2000 (30.06.2000		60/233,063	14 September 2000 (14.09.2000)	US
	60/216,647	7 July 2000 (07.07.2000		60/233,064	14 September 2000 (14.09.2000)	US
	60/216,880	7 July 2000 (07.07.2000		60/232,401	14 September 2000 (14.09.2000)	US
	60/217,487	11 July 2000 (11.07.2000		60/232,399	14 September 2000 (14.09.2000)	US
	60/217,496	11 July 2000 (11.07.2000		60/233,065	14 September 2000 (14.09.2000)	US
	60/218,290	14 July 2000 (14.07.2000	-	60/232,398	14 September 2000 (14.09.2000)	
	60/220,963	26 July 2000 (26.07.2000		60/234,274	21 September 2000 (21.09.2000)	US
	60/220,964	26 July 2000 (26.07.2000)		60/234,223	21 September 2000 (21.09.2000)	US
	60/225,757	14 August 2000 (14.08.2000		60/234,997	25 September 2000 (25.09.2000)	US
	60/225,270	14 August 2000 (14.08.2000)		60/234,998	25 September 2000 (25.09.2000)	US
	60/225,447	14 August 2000 (14.08.2000)		60/235,484	26 September 2000 (26.09.2000)	US
	60/225,267	14 August 2000 (14.08.2000)	•	60/235,834	27 September 2000 (27.09.2000)	US
	60/225,758	14 August 2000 (14.08.2000)		60/235,836	27 September 2000 (27.09.2000)	US
	60/224,518	14 August 2000 (14.08.200)		00/250,509	29 September 2000 (29.09.2000)	US
	60/224,518	14 August 2000 (14.08.200)		00/250,527	29 September 2000 (29.09.2000)	US
		14 August 2000 (14.08.200)		00/250,500	29 September 2000 (29.09.2000)	US
	60/225,268	· ·		00/200,007	29 September 2000 (29.09.2000)	US
	60/225,759	14 August 2000 (14.08.200		00/200,570	29 September 2000 (29.09.2000)	US
	60/225,214	14 August 2000 (14.08.200		00/25/,055	2 October 2000 (02.10.2000)	US
	60/225,213	14 August 2000 (14.08.200		00/237,030	2 October 2000 (02.10.2000)	US
	60/225,266	14 August 2000 (14.08.200		00/250,002	2 October 2000 (02.10.2000)	US
	60/226,279	18 August 2000 (18.08.200		00/25/,05/	2 October 2000 (02.10.2000)	US
3	60/226,868	22 August 2000 (22.08.200	0) US	60/237,040	2 October 2000 (02.10.2000)	US
A					[Continued on next p	page]

(54) Title: NUCLEIC ACIDS, PROTEINS, AND ANTIBODIES

(57) Abstract: The present invention relates to novel proteins. More specifically, isolated nucleic acid molecules are provided encoding novel polypeptides. Novel polypeptides and antibodies that bind to these polypeptides are provided. Also provided are vectors, host cells, and recombinant and synthetic methods for producing human polynucleotides and/or polypeptides, and antibodies. The invention further relates to diagnostic and therapeutic methods useful for diagnosing, treating, preventing and/or prognosing disorders related to these novel polypeptides. The invention further relates to screening methods for identifying agonists and antagonists of polynucleotides and polypeptides of the invention. The present invention further relates to methods and/or compositions for inhibiting or enhancing the production and function of the polypeptides of the present invention.



CLVV5/



60/239,935	13 October 2000 (13.10.2000)	US
60/239,937	13 October 2000 (13.10.2000)	US
60/241,809	20 October 2000 (20.10.2000)	US
60/241,785	20 October 2000 (20.10.2000)	US
60/240,960	20 October 2000 (20.10.2000)	US
60/241,787	20 October 2000 (20.10.2000)	US
60/241,786	20 October 2000 (20.10.2000)	US
60/241,826	20 October 2000 (20.10.2000)	US
60/241,808	20 October 2000 (20.10.2000)	US
60/241,221	20 October 2000 (20.10.2000)	US
60/244,617	1 November 2000 (01.11.2000)	US
60/246,532	8 November 2000 (08.11.2000)	US
60/246,474	8 November 2000 (08.11.2000)	US
60/246,475	8 November 2000 (08.11.2000)	US
60/246,525	8 November 2000 (08.11.2000)	US
60/246,528	8 November 2000 (08.11.2000)	US
60/246,477	8 November 2000 (08.11.2000)	US
60/246,476	8 November 2000 (08.11.2000)	US
60/246,526	8 November 2000 (08.11.2000)	US
60/246,613	8 November 2000 (08.11.2000)	US
60/246,609	8 November 2000 (08.11.2000)	US
60/246,478	8 November 2000 (08.11.2000)	US US
60/246,524	8 November 2000 (08.11.2000)	
60/246,523	8 November 2000 (08.11.2000)	US US
60/246,527	8 November 2000 (08.11.2000)	US
60/246,611	8 November 2000 (08.11.2000)	US
60/246,610	8 November 2000 (08.11.2000) 17 November 2000 (17.11.2000)	US
60/249,299 60/249,216	17 November 2000 (17.11.2000) 17 November 2000 (17.11.2000)	US
60/249,210	17 November 2000 (17.11.2000) 17 November 2000 (17.11.2000)	US
60/249,210	17 November 2000 (17.11.2000) 17 November 2000 (17.11.2000)	US
60/249,207	17 November 2000 (17.11.2000)	US
60/249,245	17 November 2000 (17.11.2000)	US
60/249,218	17 November 2000 (17.11.2000)	US
60/249,208	17 November 2000 (17.11.2000)	US
60/249,213	17 November 2000 (17.11.2000)	US
60/249,215	17 November 2000 (17.11.2000)	US
60/249,211	17 November 2000 (17.11.2000)	US
60/249,217	17 November 2000 (17.11.2000)	US
60/249,244	17 November 2000 (17.11.2000)	US
60/249,214	17 November 2000 (17.11.2000)	US
60/249,297	17 November 2000 (17.11.2000)	US
60/249,264	17 November 2000 (17.11.2000)	US
60/249,209	17 November 2000 (17.11.2000)	US
60/249,300	17 November 2000 (17.11.2000)	US
60/249,265	17 November 2000 (17.11.2000)	US
60/250,391	1 December 2000 (01.12.2000)	US
60/250,160	1 December 2000 (01.12.2000)	US
60/251,988	5 December 2000 (05.12.2000)	US
60/256,719	5 December 2000 (05.12.2000)	US
60/251,030	5 December 2000 (05.12.2000)	US
60/251,479	6 December 2000 (06.12.2000)	US
60/251,869	8 December 2000 (08.12.2000)	US
60/251,856	8 December 2000 (08.12.2000)	US
60/251,868	8 December 2000 (08.12.2000)	US

60/251,990	8 December 2000 (08.12.2000)	US
60/251,989	8 December 2000 (08.12.2000)	US
60/254,097	11 December 2000 (11.12.2000)	US
60/259,678	5 January 2001 (05.01.2001)	US

(71) Applicant (for all designated States except US): HUMAN GENOME SCIENCES, INC. [US/US]; 9410 Key West Avenue, Rockville, MD 20850 (US).

(72) Inventors; and

- (75) Inventors/Applicants (for US only): ROSEN, Craig, A. [US/US]; 22400 Rolling Hill Lane, Laytonsville, MD 20882 (US). BARASH, Steven, C. [US/US]; 111 Watkins Pond Boulevard, #301, Rockville, MD 20850 (US). RUBEN, Steven, M. [US/US]; 18528 Heritage Hills Drive, Olney, MD 20832 (US).
- (74) Agents: HOOVER, Kenley, K. et al.; Human Genome Sciences, Inc., 9410 Key West Avenue, Rockville, MD 20850 (US).
- (81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.
- (84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report
- with sequence listing part of description published separately in electronic form and available upon request from the International Bureau
- (88) Date of publication of the international search report: 31 January 2002

(15) Information about Correction:

Previous Correction:

see PCT Gazette No. 36/2001 of 7 September 2001, Section II

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US01/01307

A. CLASSIFICATION OF SUBJECT MATTER								
IPC(7) : C12Q 1/68; C07H 21/02								
US CL : 435/6; 536/23.1 According to International Patent Classification (IPC) or to both national classification and IPC								
B. FIELDS SEARCHED								
Minimum documentation searched (classification system followed by classification symbols) U.S.: 435/6; 536/23.1								
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched								
Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) Please See Continuation Sheet								
	SIDERED TO BE RELEVANT							
	document, with indication, where ap		Relevant to claim No.					
X LEE et al. Tra	nscriptional downregulation of gap-ju	unction proteins blocks junctional	1-3					
A communication 18, pages 1213	-1221, see entire document.	: Journal of Cell Biology, 1992, vol.	4-10 and 21					
	A1 (DANA FABER CANCER INST entire document.	ITUTE, INC.) 25 February 1993	11					
A (25.02.93), see	entire document.		12 and 14-16					
Further documents are	listed in the continuation of Box C.	See patent family annex.						
* Special categories of c "A" document defining the general of particular relevance	ited documents:	"T" later document published after the inte date and not in conflict with the applic principle or theory underlying the invo- "X" document of particular relevance; the	eation but cited to understand the ention					
	blished on or after the international filing date	considered novel or cannot be conside when the document is taken alone						
establish the publication date o specified)	ulas on priority claim(s) or which is cited to cusother citation or other special reason (as disclosure, use, exhibition or other means	"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art						
"P" document published prior to the priority date claimed	international filing date but later than the	"&" document member of the same patent family						
Date of the actual completion	of the international search	Date of mailing of the international search report						
30 July 2001 (30.07.2001)		1 6 OCT 2001						
Name and mailing address of		Authorized officer						
Commissioner of Patents Box PCT	and Trademarks	Young J. Kim						
Washington, D.C. 20231		$\mathcal{N}\mathcal{V}^{\mathcal{A}}$						
Facsimile No. (703)305-3230)	Telephone No. (703) 308-0196	J					

Form PCT/ISA/210 (second sheet) (July 1998)

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US01/01307

Box I Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)			
This international report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:			
1. Claim Nos.: because they relate to subject matter not required to be searched by this Authority, namely:			
2. Claim Nos.: because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:			
3. Claim Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).			
Box II Observations where unity of invention is lacking (Continuation of Item 2 of first sheet)			
This International Searching Authority found multiple inventions in this international application, as follows: Please See Continuation Sheet			
1. As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims. 2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee. 3. As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:			
4. No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.: 1-12, 14-16, 21, and SEQ ID NO: 11 and 490 Remark on Protest The additional search fees were accompanied by the applicant's protest. No protest accompanied the payment of additional search fees.			

Form PCT/ISA/210 (continuation of first sheet(1)) (July 1998)

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US01/01307

BOX II. OBSERVATIONS WHERE UNITY OF INVENTION IS LACKING

This application contains the following inventions or groups of inventions which are not so linked as to form a single general inventive concept under PCT Rule 13.1. In order for all inventions to be examined, the appropriate additional examination fees must be paid.

Group I, claim(s) 1-12, 14-16, and 21, drawn to cDNA, polypeptides, genes, a method of using the cDNA to make host cells comprising the cDNA, and a method of making the polypeptide.

Group II, claim(s) 13, drawn to an antibody specific for the polypeptides of Group I.

Group III, claim(s) 17 and 24, drawn to a therapeutic method of using the cDNA or the polypeptide of Group I.

Group IV, claim(s) 18 and 19, drawn to a diagnostic method of using the cDNA or polypeptide of Group I.

Group V, claim(s) 20, drawn to a method of using the polypeptide of Group I to isolate a binding partner.

Group VI, claim(s) 22, drawn to a method of using the cDNA of Group I to identify the activity of the polypeptide encoded by the cDNA.

Group VII, claim(s) 23, drawn to the binding partner made by the method of Group V.

The inventions listed as Groups I-VII do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons: PCT Rule 13.1 and Annex B do not provide for unity of invention between two or more products or methods of use that share a special technical feature. As set forth above, the Groups enumerated II-VII are additional methods/products inventions and thus, lack of unity is held in accordance with PCT Rule 13.1 and Annex B.

In addition, each Group detailed above reads on distinct Groups drawn to multiple sequences. The sequences are distinct because they are unrelated sequences, and a further lack of unity is applied to each Group. The Applicants must further elect one sequence for examination in the elected Group detailed above. Payment of fees for an additional invention will entitle the Applicants to examination of one additional sequence.

Continuation of B. FIELDS SEARCHED Item 3:

Database EST, GenEmbl

Search terms: SEQ ID Number 11 and 490